Natco Pharma is considering acquisitions to strengthen its core business: Chemical Industry Digest

Natco Pharma is considering acquisitions in the Rest of the World (ROW) markets to strengthen its core business. “The acquisition space is aimed at strengthening our core business. We have the financial capacity to do so and our focus is on RoW markets. While we are yet to complete any transaction, we are hopeful of progress in the next few years,” said Rajeev Nannapaneni, Director and CEO, Natco Pharma.

Hyderabad-based Natco has been working to expand its reach, recently investing around $2 million in Delhi-based biotech startup Cellogen Therapeutics Private Ltd. Given Natco’s strong presence in oncology, the move could benefit its business in the long run.

On the agriculture sector, Nannapaneni noted that the company’s target for FY24 was in the range of ₹ 140-150 crore but fell short by around ₹ 25 crore due to poor monsoon conditions and some profits. “Overall, this is a promising business. We have built a strong brand in a short period of time and can provide more detailed guidance on business performance around June,” he added. As reported by businessline, Natco remains optimistic about the future introduction of several generic drugs for the first time in the agriculture industry.